Regentis Biomaterials Ltd.

RGNT XASE

Market Cap

8.6M

Short interest (May 15)

0.3%

Net Short (Jun 03 ): 0.0%

Borrow Fee

12.78%

↑ 11.4%

Available Shares

6K

↓ 56.3%

Price Chart

Company Overview

Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.

Company Info

Exchange: XASE
CIK: 0001912966
Asset Type: CS

Market Data

Market Cap: $8,597,767
Employees: 8
Status: Active

Short Interest

Current Borrow Fee 12.78%
Range: 12.71% - 12.78%
Available Shares 6K
Range: 0 - 10K

Recent Changes

Fee Change: ↑ 2.4%
Available Change: ↓ 36.0%

Quick Actions

View Dilution Chart
Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam Unsubscribe anytime